It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chemokine (C–C motif) ligand 2 (CCL2) has been associated with chronic metabolic diseases. We aimed to investigate whether Ccl2 gene overexpression is involved in the regulation of signaling pathways in metabolic organs. Biochemical and histological analyses were used to explore tissue damage in cisgenic mice that overexpressed the Ccl2 gene. Metabolites from energy and one-carbon metabolism in liver and muscle extracts were measured by targeted metabolomics. Western blot analysis was used to explore the AMP-activated protein kinase (AMPK) and mammalian target of rapamycin pathways. Ccl2 overexpression resulted in steatosis, decreased AMPK activity and altered mitochondrial dynamics in the liver. These changes were associated with decreased oxidative phosphorylation and alterations in the citric acid cycle and transmethylation. In contrast, AMPK activity and its downstream mediators were increased in muscle, where we observed an increase in oxidative phosphorylation and increased concentrations of different metabolites associated with ATP synthesis. In conclusion, Ccl2 overexpression induces distinct metabolic alterations in the liver and muscle that affect mitochondrial dynamics and the regulation of energy sensors involved in cell homeostasis. These data suggest that CCL2 may be a therapeutic target in metabolic diseases.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Universitat Rovira I Virgili, Department of Medicine and Surgery, Reus, Spain (GRID:grid.410367.7) (ISNI:0000 0001 2284 9230); Hospital Universitari Sant Joan, Institut D’Investigació Sanitària Pere Virgili, Unitat de Recerca Biomèdica, Reus, Spain (GRID:grid.411136.0) (ISNI:0000 0004 1765 529X)
2 Hospital Universitari Sant Joan, Institut D’Investigació Sanitària Pere Virgili, Unitat de Recerca Biomèdica, Reus, Spain (GRID:grid.411136.0) (ISNI:0000 0004 1765 529X)
3 Institut D’Investigació Biomèdica de Bellvitge, Cell Death and Metabolism, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257)
4 Catalan Institute of Oncology, Program Against Cancer Therapeutic Resistance (ProCURE), Metabolism and Cancer Group, Girona, Spain (GRID:grid.418701.b) (ISNI:0000 0001 2097 8389); Girona Biomedical Research Institute (IDIBGI), Girona, Spain (GRID:grid.429182.4)
5 Universitat Rovira I Virgili, Department of Medicine and Surgery, Reus, Spain (GRID:grid.410367.7) (ISNI:0000 0001 2284 9230); Hospital Universitari Sant Joan, Institut D’Investigació Sanitària Pere Virgili, Unitat de Recerca Biomèdica, Reus, Spain (GRID:grid.411136.0) (ISNI:0000 0004 1765 529X); The Campus of International Excellence Southern Catalonia, Tarragona, Spain (GRID:grid.411136.0)